Get the Stockscreener App
54.24
2.65%
1.40
After Hours:
54.24
Moonlake Immunotherapeutics stock is traded at $54.24, with a volume of 78,172.
It is up +2.65% in the last 24 hours and up +16.15% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
See More
Previous Close:
$52.84
Open:
$53.09
24h Volume:
78,172
Relative Volume:
0.26
Market Cap:
$3.32B
Revenue:
-
Net Income/Loss:
$-54.80M
P/E Ratio:
-46.39
EPS:
-1.1692
Net Cash Flow:
$-64.65M
1W Performance:
+8.87%
1M Performance:
+16.15%
6M Performance:
+32.78%
1Y Performance:
+22.71%
1-Day Range:
$52.37
$54.60
1-Week Range:
$48.91
$55.81
52-Week Range:
$37.55
$64.98
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
54.24 | 3.32B | 0 | -54.80M | -64.65M | -1.1692 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Westfield Capital Management Co. LP Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $79.00 Consensus PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha
Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MoonLake Immunotherapeutics management to meet with Oppenheimer - TipRanks
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada
(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks
MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan
FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com
MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World
What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat
MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
MoonLake Reports $493.9M Cash Position, Advances Multiple Phase 3 Trials | MLTX Stock News - StockTitan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat
MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN
I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
(MLTX) Proactive Strategies - Stock Traders Daily
HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha
When (MLTX) Moves Investors should Listen - Stock Traders Daily
MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily
MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex
What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World
Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 27 '24 |
Sale |
55.00 |
62,810 |
3,454,550 |
3,043,619 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 28 '24 |
Sale |
55.00 |
56,065 |
3,083,575 |
2,987,554 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 29 '24 |
Sale |
55.89 |
4,740 |
264,919 |
2,982,814 |
| Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
31,910 |
1,755,050 |
2,925,573 |
| Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,491 |
1,622,005 |
2,957,483 |
| Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,431 |
1,618,705 |
70,071 |
| Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
28,090 |
1,544,950 |
41,981 |
| Santos da Silva Jorge | Chief Executive Officer |
Feb 21 '24 |
Sale |
55.27 |
1,125 |
62,179 |
3,106,429 |
| Reich Kristian | Chief Scientific Officer |
Feb 20 '24 |
Sale |
57.45 |
10,000 |
574,500 |
2,987,483 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):